Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong

Preventive Medicine

Volumn 45, Issue 2-3, 2007, Pages 130-134

  Lee, Peter W H ^a   Kwan, Tracy T C ^a   Tam, Kar Fai ^a   Chan, Karen K L ^a   Young, Phyllis M C ^b   Lo, Sue S T ^c   Cheung, Annie N Y ^a   Ngan, Hextan Y S ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c Family Planning Association of Hong Kong   (Hong Kong)

Author keywords

Asian women; Cervical cancer; HPV; HPV vaccination; Prevention

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; AWARENESS; CANCER PREVENTION; CANCER RISK; CHINESE; CONTROLLED STUDY; FEMALE; HEALTH BEHAVIOR; HEALTH STATUS; HONG KONG; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; ATTITUDE TO HEALTH; CHINA; FEMALE; FOCUS GROUPS; HONG KONG; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; UTERINE CERVICAL NEOPLASMS;

EID: 34548337317     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2007.07.013     Document Type: Article

References (14)

1. Brabin L., Roberts S.A., Farzaneh F., and Kitchener H.C. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine 24 (2006) 3087-3094
2. Census and Statistics Department, 2006. Quarterly report on general household survey: January to March 2006, Department, C.a.S. (ed). Hong Kong SAR Government.
3. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., Jenkins D., Schuind A., Costa Clemens S.A., and Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
4. Hong Kong Cancer Registry. Fast Stats on Cervix Cancer 2004 (2004), Hospital Authority, Hong Kong
5. Krueger R. Analyzing & Reporting Focus Group Results (1998), Sage Publications, Thousand Oaks (Calif.)
6. Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J.M., and Koutsky L.A. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
7. McCaffery K., Forrest S., Waller J., Desai M., Szarewski A., and Wardle J. Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK. Br. J. Cancer 88 (2003) 42-46
8. Morgan D. Planning Focus Groups (1998), Sage Publications, Thousand Oaks (Calif.)
9. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., Shah K.V., and Meijer C.J. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111 (2004) 278-285
10. Olshen E., Woods E.R., Austin S.B., Luskin M., and Bauchner H. Parental acceptance of the human papillomavirus vaccine. J. Adolesc. Health 37 (2005) 248-251
11. Sankaranarayanan R. Overview of cervical cancer in the developing world. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95 Suppl 1 (2006) S205-S210
12. Stanley M. HPV vaccines. Best Pract. Res. Clin. Obstet. Gynaecol. 20 (2006) 279-293
13. Tesch R. Qualitative Research: Analysis Types and Software Tools (1990), Falmer, New York
14. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., Wheeler C.M., Koutsky L.A., Malm C., Lehtinen M., Skjeldestad F.E., Olsson S.E., Steinwall M., Brown D.R., Kurman R.J., Ronnett B.M., Stoler M.H., Ferenczy A., Harper D.M., Tamms G.M., Yu J., Lupinacci L., Railkar R., Taddeo F.J., Jansen K.U., Esser M.T., Sings H.L., Saah A.J., and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278